A Study of ASP3082 in Adults With Advanced Solid Tumors with KRAS G12D Mutation
This study is testing a new treatment called ASP3082 for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D mutation. You may be able to join if you've already had standard treatments or can't receive them. Researchers want to see how safe ASP3082 is, both by itself and when given with cetuximab. The study will also look at any side effects you might experience. This is an open-label study, meaning you and the study staff will know you are receiving ASP3082. The goal is to find the best dose of ASP3082 to use in future studies.
- Study design
- This is an open-label study, meaning everyone knows what treatment is being given. It aims to enroll 681 participants and is designed in two parts to find suitable doses of ASP3082.
- What's involved
- In Part 1, you would receive ASP3082, either alone or with cetuximab, through an intravenous infusion. Medical problems will be recorded at each dose to find suitable doses.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your adverse events and serious adverse events will be measured for up to 48 months after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05382559
A Study of ASP3082 in Adults With Advanced Solid Tumors
Recruiting
PHASE1Ages 18+InterventionalTreatmentAstellas Pharma Inc
~681 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:SetidegrasibCetuximabLeucovorinOxaliplatinFluorouracilIrinotecan
At a glance
Recruiting sites
65 of 66 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Dose Limiting Toxicities (DLTs)
Measured over Up to 28 Days
+7 more outcomes measured
Conditions
Where it's being run
66 sites across 43 statesSpain8
New York4
Florida3
France3
Seoul3
California2
Massachusetts2
Ohio2
Study leadership
- Medical Director · STUDY_DIRECTOR · Astellas Pharma Inc
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participant has locally advanced (unresectable) or metastatic solid tumor malignancy with documented Kirsten rat sarcoma viral oncogene homolog \[KRAS\] G12D mutation and has received prior standard therapy and the investigator does not see any further clinical benefit from continuing such targeted therapy, or is ineligible to receive standard approved therapies (no limit to the number of prior treatment regimens).
For the ASP3082 monotherapy escalation cohorts, participants with solid tumor malignancies are allowed to be enrolled. Participants with other known KRAS G12 mutations will not be eligible for the study
For ASP3082 combination therapy with Nab-P+GEM or FOLFIRINOX or NALRIFOX: Participant must have mPDAC that has not been previously treated with chemotherapy. If a participant received (neo)adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the (neo)adjuvant therapy.
Participant consents to provide tumor specimen in a tissue block or unstained serial slides or a tumor biopsy (core needle biopsy or excision) obtained after the last interventional treatment, but prior to start of study intervention. Participant also consents to provide a sample for tumor biopsy during the treatment period as indicated in the study protocol. If a participant cannot provide a fresh tissue biopsy sample, the site should consult with the sponsor/study medical monitor.
Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
Participant has an ECOG performance status of 0, 1 or 2 for dose escalation, and 0 or 1 for dose expansion.
Participant's last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5 half-lives, whichever is shorter, prior to initiation of study intervention administration.
Participant has completed any radiotherapy (including stereotactic radiosurgery) at least 14 days prior to the start of study intervention administration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids (NOTE: Physiologic replacement dose of hydrocortisone or its equivalent \[defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone, or up to 10 mg per day of prednisone\] is permitted), and not have active radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\<= 2 weeks of radiotherapy) to non-central nervous system disease.
Participant's adverse events \[AEs\] (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 14 days prior to start of study intervention (or prior to staring SoC chemotherapy, for first line (1L) participants receiving Nab-P+GEM FOLFIRINOX or NALIRIFOX.
Participant has adequate organ function as indicated by protocol laboratory value parameters (If a participant has received a recent blood transfusion, the laboratory tests must be obtained \>= 14 days after any blood transfusion.).
Female participant is not pregnant, confirmed by pregnancy test and medical evaluation by interview, and at least 1 of the following conditions apply:
Not a woman of childbearing potential (WOCBP).
WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after study intervention administration.
EU only: For combination therapy with carboplatin, follow contraception guidelines from the time of informed consent through at least 7 months after the final dose of carboplatin.
South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 15 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 14 months after the final dose of cisplatin.
Female participant must agree not to breastfeed starting at screening and throughout the study period and for 6 months after study intervention administration.
Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 6 months after study intervention administration.
Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after study intervention administration.
Male participant must not donate sperm during the treatment period and for 3 months after study intervention administration.
South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 12 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 11 months after the final dose of cisplatin.
Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after study intervention administration.
Participant agrees not to participate in another interventional study while receiving study intervention (Participants who are currently in the follow-up period of an interventional clinical trial are allowed).
For ASP3082 Combination Therapy with Pembrolizumab (Cohort G), or Platinum-based Chemotherapy + Pemetrexed +/- Pembrolizumab (Cohort H): Participant must have pathologically documented locally advanced or metastatic (unresectable Stage IIIB-IV) non-small cell lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and
have received prior platinum-containing chemotherapy (safety lead-in only) or
have never received systemic therapy (up to 1 cycle of SoC pembrolizumab \[defined as one 21-day cycle of 200 mg\] in Cohort G and up to 1 cycle of SoC platinum-based chemotherapy ± pembrolizumab \[defined as one 21-day cycle of 200 mg\] or pembrolizumab \[defined as one 21-day cycle of 200 mg\] in Cohort H is permitted prior to Screening, provided a 21-day washout occurs before C1D1) for locally advanced or metastatic NSCLC with no oncogenic driver mutations. Participants who received adjuvant or neoadjuvant platinum-based chemotherapy and developed recurrent or metastatic disease more than 12 months after completing therapy may be enrolled.
Exclusion
Participant has received investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to start of study intervention.
Participant has symptomatic or untreated central nervous system (CNS) metastases. Participants with asymptomatic, treated CNS metastases are eligible.
Participant has leptomeningeal disease as a manifestation of the current malignancy.
Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.
Participant has a known or suspected hypersensitivity to ASP3082 or any components of the formulation used.
Participant with active hepatitis B (including acute hepatitis B virus \[HBV\] or chronic HBV) or hepatitis C virus \[HCV\] (ribonucleic acid \[RNA\] detected by qualitative assay). HCV RNA testing is not required in participants with negative HCV antibody testing.
Participant has a known history of human immunodeficiency virus \[HIV\] infection. No HIV testing is required unless mandated by a local health authority.
Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study intervention, left ventricular ejection fraction (LVEF) \< 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO) or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker, or long QT syndrome.
Participant has a corrected QT interval (single electrocardiogram \[ECG\]) using Fridericia's formula (QTcF) \> 450 milliseconds (msec) (men) or \>470 msec (women) during screening.
Participant has received prior treatment with a specific KRAS G12D inhibitor/degrader or pan-RAS inhibitor/degrader targeting KRAS G12D. Participants who received prior treatment with a KRAS G12D inhibitor/degrader are eligible for the ASP3082 combination therapy cohort.
Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.
Participant is expected to require another form of antineoplastic therapy while on study treatment.
Participant has any condition which makes the participant unsuitable for study participation (such as psychiatric illness/social situations that would limit compliance with study requirements).
Participant has had major surgery within 4 weeks prior to first dose of study intervention.
Prior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximab.
History of interstitial lung disease requiring systemic steroid treatment. Note that a participant with resolved pulmonary infections or radiation pneumonitis is eligible.
What this trial measures
- Incidence of Dose Limiting Toxicities (DLTs)Up to 28 Days
A DLT is defined as any event meeting the DLT criteria excluding toxicities clearly related to disease progression or intercurrent illness or standard of care (SoC) regimens as determined by the investigator.
- Number of Participants with Adverse Events (AEs)Up to 48 months
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study IP, whether or not considered related to the study investigational product (IP). Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures.
- Number of Participants with Serious Adverse Events (SAEs)Up to 48 months
An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events.
- Number of Participants with laboratory value abnormalities and/or adverse events (AEs)Up to 48 months
Number of participants with potentially clinically significant laboratory values.
- Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)Up to 48 months
Number of participants with potentially clinically significant ECG values.
- Number of Participants with vital sign abnormalities and/or adverse events (AEs)Up to 48 months
Number of participants with potentially clinically significant vital sign values.
- Number of Participants with physical exam abnormalities and/or adverse eventsUp to 48 months
Number of participants with potentially clinically significant physical exam values.
- Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance statusUp to 48 months
The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.